NCRI 2018 | IO-chemo and IO-radio options for cancer treatment
John Bell
• 8 Nov 2018
John Bell, PhD, from the University of Ottawa, Ottawa, Canada, discusses the huge contribution of immunotherapy to the field of cancer therapeutics, while highlighting the need for further improvements to increase the number of patients cured. In this video, Dr Bell explores potential combinations involving radiotherapy, chemotherapy, immune checkpoint antibodies, engineered T-cells and oncolytic viruses, highlighting the need to strategically determine the most appropriate combinations in patients. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.
